ClinicalTrials.gg
CompletedNCT01989143Updated Oct 19, 2023

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

A Phase 1 interventional study of PF-06480605 and Placebo in Healthy, sponsored by Telavant, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by Telavant, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This single and multiple ascending dose study is a first in human assessment of PF-06480605. The goal is to study the safety, tolerability, pharmacokinetics and pharmacodynamics.

02

Conditions studied

  • Healthy

Keywords

  • Phase 1
  • Randomized
  • Double-blind
  • Placebo-controlled
  • Dose escalating
  • Single and Multiple doses
  • Safety
  • Tolerability
  • PK/PD
  • PF-06480605
03

In context

Lead sponsor

Telavant, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

First submitted before Telavant, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects of non between the ages of 18 and 55 years, inclusive (Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead and clinical laboratory tests).
  • Female subjects of non childbearing potential must meet at least one of the following criteria:

    1. Achieved status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females;
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.
  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
  • Evidence of a personally signed and dated document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  • X-ray with no evidence of current, active TB or previous inactive TB, general infections, heart failure, , or other clinically significant abnormalities taken at Screening or within 3 months prior to Day 1 and read by a qualified radiologist.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Subjects with a history of or current positive results for any of the following serological tests: surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), anti antibody (HCV Ab) or (HIV).
  • Subjects with a history of disorders.
  • Subjects with a history of allergic or anaphylactic reaction to a therapeutic drug.
  • History of tuberculosis or active, latent or inadequately treated tuberculosis infection.
  • Treatment with an drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half lives or 180 days for biologics preceding the first dose of study medication.
  • Pregnant females; breastfeeding females; and females of .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    SAD Cohorts 1-8 Experimental Arm

    Drug: PF-06480605

  • Placebo comparator
    SAD Cohorts 1-8 Placebo Arm

    Drug: Placebo

  • Experimental
    MAD Cohorts 9-11 Experimental Arm

    Drug: PF-06480605

  • Placebo comparator
    MAD Cohorts 9-11 Placebo Arm

    Drug: Placebo

  • Experimental
    MAD Cohort 12 Experimental Arm

    Drug: PF-06480605

  • Placebo comparator
    MAD Cohort 12 Placebo Arm

    Drug: Placebo

Interventions

  • Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.

  • DrugPlacebo

    Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.

  • Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).

  • DrugPlacebo

    Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).

  • Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).

  • DrugPlacebo

    Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting or intolerability treatment related adverse events (AEs).

    Time frame: 6 weeks

  2. Incidence, severity and causal relationship of treatment emergent AEs (TEAEs) and withdrawals due to treatment emergent adverse events.

    Time frame: 6 weeks

  3. Incidence and magnitude of abnormal laboratory findings.

    Time frame: 6 weeks

  4. Abnormal and clinically relevant changes in vital signs, blood pressure (BP) and electrocardiogram (ECG) parameters.

    Time frame: 6 weeks

Secondary outcomes

  1. Single Ascending Dose: Maximum Observed Plasma Concentration (Cmax)

    Time frame: 6 weeks

  2. Single Ascending Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 6 weeks

  3. Single Ascending Dose: Area under the plasma concentration-time profile from time zero to 14 days (AUC14 days)

    Time frame: 6 weeks

  4. Single Ascending Dose: Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)

    Time frame: 6 weeks

  5. Single Ascending Dose: Area under the plasma concentration-time profile from time zero to the time of last quantifiable concentration (AUClast)

    Time frame: 6 weeks

  6. Single Ascending Dose: Dose normalized maximum plasma concentration (Cmax[dn])

    Time frame: 6 weeks

  7. Single Ascending Dose: Dose normalized area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf[dn])

    Time frame: 6 weeks

  8. Single Ascending Dose: Dose normalized area under the plasma concentration-time profile from time zero to the time of last quantifiable concentration (AUClast[dn])

    Time frame: 6 weeks

  9. Single Ascending Dose: Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 6 weeks

  10. Single Ascending Dose: Mean residence time(MRT)

    Time frame: 6 weeks

  11. Single Ascending Dose: Volume of Distribution at Steady State (Vss)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: 6 weeks

  12. Single Ascending Dose: Systemic Clearance (CL)

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: 6 weeks

  13. Multiple Ascending Dose First Dose: Maximum Observed Plasma Concentration (Cmax)

    Time frame: 6 weeks

  14. Multiple Ascending Dose First Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 6 weeks

  15. Multiple Ascending Dose First Dose: Area under the plasma concentration-time profile from time zero to time τ, the dosing interval where τ=2 weeks (AUCτ)

    Time frame: 6 weeks

  16. Multiple Ascending Dose First Dose: Dose normalized maximum plasma concentration (Cmax[dn])

    Time frame: 6 weeks

  17. Multiple Ascending Dose First Dose: Dose normalized Area under the plasma concentration-time profile from time zero to time τ, the dosing interval where τ=2 weeks (AUCτ [dn])

    Time frame: 6 weeks

  18. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 6 weeks

  19. Multiple Ascending Dose First Dose: Mean residence time (MRT)

    Time frame: 6 weeks

  20. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 6 weeks

  21. Multiple Ascending Dose First Dose: Volume of Distribution at Steady State (Vss)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: 6 weeks

  22. Multiple Ascending Dose First Dose: Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 6 weeks

  23. Multiple Ascending Dose First Dose: Systemic Clearance (CL)

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: 6 weeks

  24. Multiple Ascending Dose Multiple Dose: Maximum Observed Plasma Concentration (Cmax)

    Time frame: 6 weeks

  25. Multiple Ascending Dose Multiple Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 6 weeks

  26. Multiple Ascending Dose Multiple Dose: Area under the plasma concentration-time profile from time zero to time τ, the dosing interval where τ=2 weeks (AUCτ)

    Time frame: 6 weeks

  27. Multiple Ascending Dose Multiple Dose: Dose normalized maximum plasma concentration (Cmax[dn])

    Time frame: 6 weeks

  28. Multiple Ascending Dose Multiple Dose: Dose normalized Area under the plasma concentration-time profile from time zero to time τ, the dosing interval where τ=2 weeks (AUCτ [dn])

    Time frame: 6 weeks

  29. Multiple Ascending Dose Multiple Dose: Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 6 weeks

  30. Multiple Ascending Dose Multiple Dose: Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 6 weeks

  31. Multiple Ascending Dose Multiple Dose: Volume of Distribution at Steady State (Vss)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.

    Time frame: 6 weeks

  32. Multiple Ascending Dose Multiple Dose: Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 6 weeks

  33. Multiple Ascending Dose Multiple Dose: Systemic Clearance (CL)

    CL is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: 6 weeks

  34. Multiple Ascending Dose Multiple Dose: Minimum Observed Plasma Trough Concentration (Cmin)

    Time frame: 6 weeks

  35. Multiple Ascending Dose Multiple Dose: Average concentration at steady state (Cav)

    Time frame: 6 weeks

  36. Multiple Ascending Dose Multiple Dose: Observed accumulation ratio (Rac)

    Time frame: 6 weeks

  37. Multiple Ascending Dose Multiple Dose: Peak to trough fluctuation (PTF)

    Time frame: 6 weeks

  38. Multiple Ascending Dose Additional Parameter: estimate of bioavailability (F) for subcutaneous administration at the corresponding intravenous dose

    Time frame: 6 weeks

  39. Immunogenicity for both Single Ascending Dose and Multiple Ascending Dose: Development of anti-drug antibodies (ADA)

    Time frame: 6 weeks

07

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Publications

  • Banfield C, Rudin D, Bhattacharya I, Goteti K, Li G, Hassan-Zahraee M, Brown LS, Hung KE, Pawlak S, Lepsy C. First-in-human, randomized dose-escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF-06480605 in healthy subjects. Br J Clin Pharmacol. 2020 Apr;86(4):812-824. doi: 10.1111/bcp.14187. Epub 2020 Jan 28. PubMed 31758576 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2013
First posted
Nov 20, 2013
Start
Dec 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01989143
Lead sponsor
Telavant, Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Dec 2013
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Oct 19, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion